药物警戒快讯（Pharmacovigilance alert）.docVIP

药物警戒快讯（Pharmacovigilance alert） The United States warns that pregnant women taking topiramate may lead to neonatal cleft lip In March 4, 2011, the U.S. Food and Drug Administration (FDA) released information that the new data show that pregnant women using topiramate (topiramate) increased the risk of birth infants with cleft lip and / or palate. Topiramate is an anticonvulsant approved by FDA, which is used alone or in combination with other drugs to treat epilepsy. FDA also approved the drug for migraine treatment, but not for migraine symptoms. Topiramate is frequently used for other diseases, some of which may not be serious. ? if prescribing topiramate is prescribed for women of childbearing age, doctors should recommend that women who do not intend to become pregnant use effective methods of contraception. Keep in mind that the combination of estrogen containing contraceptives and topiramate may lead to lower levels of hormone exposure and a reduction in contraceptive efficacy. The United States released abacavir and heart attack the latest assessment results In March 1, 2011, the U.S. Food and Drug Administration (FDA) released the abacavir (abacavir) the latest results of the assessment and the risk of a heart attack. Abacavir is an antiviral drug, HIV-1 and other antiretroviral agents for the treatment of infection. In several observational studies of abacavir and a randomized controlled trial was observed in heart attack (myocardial infarction) increase the risk, but in other randomized controlled trials and security of the database maintained by the drug manufacturer, without observable risk of heart attack increases. Therefore, randomized clinical trials of FDA abacavir performed a meta-analysis of the results did not show the use of abacavir will lead to increased risk of myocardial infarction. The European Union revised the insulin prospectus warning against the risks associated with pioglitazone The European Committee for medicinal products for human